Flow cytometry has evolved over the past 30 y from a niche laboratory technique to a routine tool used by clinical pathologists and immunologists for diagnosis and monitoring of patients with cancer and immune deficiencies. Identification of novel patterns of expressed Ags has led to the recognition of cancers with unique pathophysiologies and treatment strategies. FACS had permitted the isolation of tumor-free populations of hematopoietic stem cells for cancer patients undergoing stem cell transplantation. Adaptation of flow cytometry to the analysis of multiplex arrays of fluorescent beads that selectively capture proteins and specific DNA sequences has produced highly sensitive and rapid methods for high through-put analysis of cytokines, Abs, and HLA genotypes. Automated data analysis has contributed to the development of a “cytomics” field that integrates cellular physiology, genomics, and proteomics. In this article, we review the impact of the flow cytometer in these areas of medical practice.

Flow cytometry began as “micro-fluorimetry” in the 1960s as an analytic technique to measure the properties of individual cells in a fluid stream following illumination with a laser (1). Fig. 1A shows the basic operation of a flow cytometer, with an example of flow cytometric analysis of FOXP3+ regulatory T cells in Fig. 1B. By breaking the fluid stream into a series of small droplets, segregating individual cells into a minority of the formed droplets, and quickly interrogating the light properties of individual droplets following laser illumination, droplets containing single cells could be electrostatically charged and separated from the majority of the cells in the fluid stream by deflecting the droplets into collection tubes during their flight in air using charged deflector plates (2). The harnessing of mAbs that specifically bound to cell surface markers (3) and the discovery of a variety of fluorescent dyes with narrow excitation and emission spectra (4) allowed the application of this technology to basic immunology research, clinical immunology diagnostics, and cell selection for preclinical models and clinical trials of transplanting phenotypically defined cell subsets. The timeline for the technical milestones of flow cytometry is shown in Fig. 2, with the introduction of clinical applications of flow cytometry shown in Table I. This review highlights the emerging clinical applications of flow cytometry and describes the unique bioinformatics issues that must be addressed when large list-mode files containing data on six or more parameters from millions of analyzed cells are generated from clinical samples.

FIGURE 1.

Schematic of FACS and an example of data. (A) Cells suspended in a core stream (green) are carried in sheath fluid (light gray) to the flow cell (yellow sphere) where they are interrogated by an excitation laser beam. Cells in the stream are detected by light scattered through the cells forward scatter (FSC) and orthogonal to the cells side scatter (SSC); cells labeled with fluorescently labeled mAbs are detected by emitted fluorescent light (FL1). Following detection of FSC, SSC, and FL1 signals, droplets are formed and loaded with positive or negative electrostatic charges. Droplets containing single cells are deflected to the left or right by highly charged metal plates, and sorted cells are collected into tubes. (B) FOXP3+ CD4+ regulatory T cells are identified from a mixture of lymphocytes using multiparameter flow cytometry.

FIGURE 1.

Schematic of FACS and an example of data. (A) Cells suspended in a core stream (green) are carried in sheath fluid (light gray) to the flow cell (yellow sphere) where they are interrogated by an excitation laser beam. Cells in the stream are detected by light scattered through the cells forward scatter (FSC) and orthogonal to the cells side scatter (SSC); cells labeled with fluorescently labeled mAbs are detected by emitted fluorescent light (FL1). Following detection of FSC, SSC, and FL1 signals, droplets are formed and loaded with positive or negative electrostatic charges. Droplets containing single cells are deflected to the left or right by highly charged metal plates, and sorted cells are collected into tubes. (B) FOXP3+ CD4+ regulatory T cells are identified from a mixture of lymphocytes using multiparameter flow cytometry.

Close modal
FIGURE 2.

Milestones in flow cytometry. Key events in the development of flow cytometry are shown in a vertical timeline (left panel), with the number of publications/y identified in http://apps.webofknowledge.com listing “microfluorimetry or flow cytometry” as key words (right panel).

FIGURE 2.

Milestones in flow cytometry. Key events in the development of flow cytometry are shown in a vertical timeline (left panel), with the number of publications/y identified in http://apps.webofknowledge.com listing “microfluorimetry or flow cytometry” as key words (right panel).

Close modal
Table I.
Summary of clinical applications of flow cytometry
Clinical SituationCell/Analyte of InterestPatient Specimen TypesPeriod of Clinical Use
Cancer Diagnosis of hematolymphoid cancers (mostly leukemias/lymphomas) Cancer cells Blood, bone marrow, various tissues Early 1980s 
 Determine cell DNA content for prognosis (e.g. childhood lymphoblastic leukemia) Cancer cells Blood, bone marrow Late 1980s 
 Monitoring of hematolymphoid cancers after therapy Residual cancer cells Blood, bone marrow Early 1990s 
Immunologic diseases Diagnosis and monitoring of HIV/AIDS CD4+ and CD8+ T cell subsets Blood Early 1980s 
 Diagnosis of primary immunodeficiencies B cells, T cells, and T cell subsets Blood, lymphoid tissues Late 1980s 
Cell therapy and transplantation Determine adequacy of hematopoietic stem cell grafts (bone marrow transplantation) to repopulate bone marrow CD34+ stem cells Stem cell graft Early 1990s 
 Risk assessment for graft rejection of solid organs and graft-versus-host disease after hematopoietic stem cell transplantation Abs to HLA proteins Recipient’s serum Early 2000s 
  HLA genotype genomic DNA Donor’s blood cells Middle 2000s 
Clinical SituationCell/Analyte of InterestPatient Specimen TypesPeriod of Clinical Use
Cancer Diagnosis of hematolymphoid cancers (mostly leukemias/lymphomas) Cancer cells Blood, bone marrow, various tissues Early 1980s 
 Determine cell DNA content for prognosis (e.g. childhood lymphoblastic leukemia) Cancer cells Blood, bone marrow Late 1980s 
 Monitoring of hematolymphoid cancers after therapy Residual cancer cells Blood, bone marrow Early 1990s 
Immunologic diseases Diagnosis and monitoring of HIV/AIDS CD4+ and CD8+ T cell subsets Blood Early 1980s 
 Diagnosis of primary immunodeficiencies B cells, T cells, and T cell subsets Blood, lymphoid tissues Late 1980s 
Cell therapy and transplantation Determine adequacy of hematopoietic stem cell grafts (bone marrow transplantation) to repopulate bone marrow CD34+ stem cells Stem cell graft Early 1990s 
 Risk assessment for graft rejection of solid organs and graft-versus-host disease after hematopoietic stem cell transplantation Abs to HLA proteins Recipient’s serum Early 2000s 
  HLA genotype genomic DNA Donor’s blood cells Middle 2000s 

A growing body of literature supports the application of flow cytometry in disease prognostication and monitoring of patients with hematological malignancies (5, 6), as well as in clinical studies of immune status in patients with cancer, immune deficiency, and allogeneic stem cell and organ transplants. More than 50 y ago, when morphology was essentially the sole diagnostic modality, only a handful of distinct hematolymphoid neoplasms, such as Hodgkin lymphoma, was recognized. A critical component of the current classification of hematolymphoid neoplasms is determination of the best-fit, nonneoplastic immune cell lineage (e.g., B cell, T cell) and differentiation state (e.g., precursor, mature) to which the Ag expression profiles point. The current international classification of hematolymphoid neoplasms, with rare exceptions, requires that the immunophenotype be integrated with morphologic, cytogenetic, and molecular genetic data to render accurate diagnoses (7). More recent advances in identifying rare immune cell subsets, such as plasmacytoid dendritic cells, and in producing Abs to selectively detect these subsets have been translated to further refinements in disease classification (8).

Flow cytometry analysis can provide important diagnostic and prognostic information and identify with high accuracy the distinctive immunophenotype of malignancies and cell DNA content that are used to select specific therapies. For example, various CD20+ B cell malignancies are now commonly treated with anti-CD20 Abs (rituximab), and a subset of CD52-expressing T cell and B cell malignancies may be treated with anti-CD52 (alemtuzumab). Flow cytometry is used to distinguish mantle cell lymphoma, an aggressive disorder that requires more intensive therapy, from other more indolent mature CD20+ B cell lymphomas with similar morphology (9). Because the Ag-expression profiles of these B cell neoplasms can be subtly different, flow cytometry can facilitate diagnosis by identifying reproducible expression patterns of multiple Ags associated with specific neoplasms and relatively quantify Ag density on malignant cells (9). The power of the flow cytometer to detect minute quantities of specific cells in heterogeneous cell mixtures is used to identify residual malignant cells after therapy, known as minimal residual disease monitoring, in common malignancies for which disease persistence portends a worse prognosis (10). Lastly, flow cytometry is a rapid means of determining relative cell DNA content for acute lymphoblastic leukemia, the most common childhood blood cancer, which helps to guide treatment.

The flow cytometer also serves as a principal clinical laboratory platform for assessing the immune status of patients, including determination of CD4+ T cell blood counts after HIV infection (11) and classification and prognostication of various primary immune deficiencies, such as autoimmune lymphoproliferative syndrome, severe combined immune deficiency, and Ab deficiencies (12). Moreover, flow cytometric quantification of specific immune cell subsets in an allogeneic stem cell graft and of immune reconstitution following allogeneic bone marrow transplantation serves as predictors of survival posttransplant (13, 14). Lastly, the flow cytometric quantification of extremely rare CD34+ endothelial progenitor cells in the blood represents a novel method to predict clinical outcomes in patients with peripheral arterial and cardiovascular disease (15, 16).

The flow cytometer has also been used as a research tool to purify specific cell populations for cell-based therapy. The identification of CD34+ as a marker for human hematopoietic stem and progenitor cells (17) led to interest in using flow cytometry to isolate and purify populations of phenotypically defined CD34+ cells for transplantation. The rationale for this approach was that patients with cancer can be treated with high-intensity chemotherapy and radiation, followed by autologous stem cell rescue to achieve remission of malignancies that relapsed after conventional chemotherapy or for which conventional chemotherapy was inadequate for long-term remissions. The clinical use of cytometry-based FACS for isolation of autologous CD34+ stem cells allowed the possibility of achieving a clinically significant depletion of contaminating tumor cells, reducing the risk for disease progression from the reinfusion of contaminating tumor cells in the stem cell graft. Protocols for the study of autologous transplantation of patients with breast cancer, non-Hodgkin’s lymphoma, and multiple myeloma using highly purified flow cytometry-sorted CD34+ progenitors were initiated (1822) (Table II). The results of these studies established the “proof-of-concept” that transplantation of highly purified hematopoietic stem cells led to durable hematopoietic reconstitution and suggest that transplantation of autologous stem cell products with >5-log ex vivo tumor cell depletion may lead to durable remissions in patients with relapsed cancer (16). The small size of these studies and the lack of a control group precludes application for U.S. Food and Drug Administration approval. Although flow cytometry can identify other cellular subsets of therapeutic interest, such as FOXP3+ regulatory T cell staining (Fig. 1B), techniques that use fixation preclude isolation of viable cells for therapeutic administration by FACS (23).

Table II.

Summary of published results from clinical studies of autologous stem cell transplantation in cancer patients using FACS-purified CD34+ hematopoietic cell progenitors

ReferencesNo. of Transplanted Patients and DiseaseAg Selection/Transplanted Cell DoseTumor Cell Contamination Pre-/Postcell SortingEngraftment Absolute Neutrophil Count > 500/μl (d)T Cell Immune ReconstitutionLong-Term Outcome
Bomberger et al. (18) 9 non-Hodgkin’s lymphoma 1.9 × 106 CD34+ cells/kg Not reported 11 300 CD3+ cells/μl at 6 mo; restricted Vβ TCR repertoire Not reported 
Tricot et al. (19) 9 myeloma 1 × 106 CD34+ CD90low cells/kg  16 Not reported Not reported 
Müller et al. (20) 22 breast cancer 1.1 × 106 CD34+ CD90low+ cells/kg 245,470-fold depletion with multiparameter sorting versus 501-fold depletion with CD34+ selection 10 700 CD3+ cells/μl at 12 mo 23% alive at 10 years; 18% disease free-survival 
Michallet et al. (21) 23 myeloma 0.7 × 106 CD34+ CD90low+ cells/kg Not reported 11 800 CD3+ cells/μl at 6 mo Not reported 
Vose et al. (22) 26 non-Hodgkin’s lymphoma 0.5 × 106 CD34+ CD90low cells/kg 3.3–5.7 log reduction 12 419 CD3+ cells/μl at day 100 70% overall survival at 4 y; 55% event-free survival at 4 y 
ReferencesNo. of Transplanted Patients and DiseaseAg Selection/Transplanted Cell DoseTumor Cell Contamination Pre-/Postcell SortingEngraftment Absolute Neutrophil Count > 500/μl (d)T Cell Immune ReconstitutionLong-Term Outcome
Bomberger et al. (18) 9 non-Hodgkin’s lymphoma 1.9 × 106 CD34+ cells/kg Not reported 11 300 CD3+ cells/μl at 6 mo; restricted Vβ TCR repertoire Not reported 
Tricot et al. (19) 9 myeloma 1 × 106 CD34+ CD90low cells/kg  16 Not reported Not reported 
Müller et al. (20) 22 breast cancer 1.1 × 106 CD34+ CD90low+ cells/kg 245,470-fold depletion with multiparameter sorting versus 501-fold depletion with CD34+ selection 10 700 CD3+ cells/μl at 12 mo 23% alive at 10 years; 18% disease free-survival 
Michallet et al. (21) 23 myeloma 0.7 × 106 CD34+ CD90low+ cells/kg Not reported 11 800 CD3+ cells/μl at 6 mo Not reported 
Vose et al. (22) 26 non-Hodgkin’s lymphoma 0.5 × 106 CD34+ CD90low cells/kg 3.3–5.7 log reduction 12 419 CD3+ cells/μl at day 100 70% overall survival at 4 y; 55% event-free survival at 4 y 

Another emerging use of flow cytometry is the measurement of Abs to HLA molecules, potentially developed after exposure through blood transfusions, prior transplantation, or pregnancy, as well as determination of HLA genotypes for transplantation. Initially performed using cumbersome and insensitive serological assays, human histocompatibility testing has moved to the forefront in using multiplexing technology, especially in providing detailed HLA Ab analysis and molecular HLA typing. In 1983, a seminal publication (24) demonstrated that donor-directed HLA Abs detectable only by flow cytometry could pose a significant risk for early kidney allograft rejection and loss. Since then, numerous studies confirmed this observation, not only for recipients of kidney allografts but for other solid organ transplants as well (25, 26). In hematology, the ability to unambiguously identify HLA Abs directed against mismatched HLA Ags in unrelated stem cell transplantation led to the recognition that these Abs can cause engraftment failure (27, 28). In some instances, the identification of donor-specific HLA Abs may be a contraindication for transplantation, whereas, in other situations, Ab-reduction protocols prior to stem cell infusion can be instituted.

The clinical use of cytometry was accelerated by the development of a new approach to detect HLA Abs using small plastic spheres (microparticles) for interrogation by a flow cytometer. The use of microparticles displaying purified Class I or Class II HLA Ags conjugated on their surfaces markedly reduced false reactions due to non-HLA cell membrane proteins associated with using whole cells as targets. Recently, a new cytometry-based multiplexing platform (29) has emerged that can simultaneously identify 100 unique two-color fluorescent microparticles displayed as a two-dimensional virtual array. Fig. 3 shows an example of sophisticated gating strategies that permit the independent analysis of each individual microparticle within the array using a third (reporter) color. The reactivity of each bead, as determined by the intensity of the “reporter” fluorescence, determines whether a reaction is considered positive or negative. HLA Ag-coated microparticles can be used to identify the Class I and/or Class II Abs from the sera of sensitized patients. Compelling studies demonstrated a strong correlation between a positive flow cytometric cross-match due to microparticle proven donor-specific Ab and early rejection and graft loss (30). The implementation of this new technology led to significant changes in allocation of solid organs to sensitized recipients throughout the United States (31).

FIGURE 3.

Generation of a virtual 10 × 10 data matrix using fluorescently labeled beads. Data are generated by a multiplexing, bead-based flow cytometry method. Individual beads are identified within a two-dimensional matrix by their unique and reproducible fluorescence signature derived from their incorporation of differing quantities of two classifier dyes (x- and y-axes). For a given combination of the classifier dyes (x, z), specific measurements of a test analyte are assessed by a “reporter” fluorescent molecule and are measured on the vertical or z-axis. The intensity of the fluorescence from the reporter molecule is proportional to the amount of specific binding of the “reporter” fluorescent probe to the bead. In this example, 10 beads have reporter fluorescence that is above the baseline background.

FIGURE 3.

Generation of a virtual 10 × 10 data matrix using fluorescently labeled beads. Data are generated by a multiplexing, bead-based flow cytometry method. Individual beads are identified within a two-dimensional matrix by their unique and reproducible fluorescence signature derived from their incorporation of differing quantities of two classifier dyes (x- and y-axes). For a given combination of the classifier dyes (x, z), specific measurements of a test analyte are assessed by a “reporter” fluorescent molecule and are measured on the vertical or z-axis. The intensity of the fluorescence from the reporter molecule is proportional to the amount of specific binding of the “reporter” fluorescent probe to the bead. In this example, 10 beads have reporter fluorescence that is above the baseline background.

Close modal

Interestingly, this multiplexing flow cytometry methodology can also be used for HLA genotyping by attaching individual DNA probes to microparticles and simultaneously testing for ∼100 HLA allele variations (32). Thus, high-volume HLA genotyping can now be performed easily in any HLA laboratory with a flow cytometer. In fact, this technology is sensitive and specific enough to accurately detect clinically significant single amino acid sequence differences predicted between HLA molecules for patients undergoing stem cell or solid organ transplantation (28, 32).

The use of multiplexed bead assays and DNA ploidy assays in high-throughput diagnostic or prognostic evaluations and studies involving detection of rare cell subsets can result in the acquisition of exceedingly large datasets. Progress in data sharing is hampered by the lack of standardization in data analysis and reporting, as well as a means of efficiently sharing large datasets for independent evaluation and collaboration across different sites. For example, data analysis tends to be intuitively based on serial evaluations of two-dimensional plots, which represents a significant source of variation that limits standardization and reproducibility in data interpretation. To maximize the potential of flow cytometry for clinical use and investigation, informatics systems, such as those applied in analyses of massive genomics and proteomics datasets, will need to be integrated with data-collection efforts.

The emerging field of “cytomics” represents an integrated, whole-cell–based description of cellular physiology that includes aspects of genomics (genes and regulatory processes) and proteomics (protein abundance and structure) endeavors to develop a more comprehensive picture of the biology of individual cells. The flow cytometer represents a logical platform upon which to build this field. However, a major challenge will be to develop standardized algorithms that allow combining and comparing datasets from different platforms to foster analytical reproducibility and allow informative meta-analyses.

Automated systems for flow cytometry data analysis are being developed that use standardized ontologies and methods that treat such datasets as statistical objects embedded in n-dimensional space or clustered distributions that may be compared with one another to foster objective data capture, evaluation, and reporting. New data standards and elements that incorporate variables of experimental protocols for data acquisition and methods used for postprocessing data analysis and interpretation will be required as well. In aggregate, these developments will advance the clinical use of flow cytometry and broaden its applications in the investigation of disease beyond hematologic malignancies and immune monitoring into a new age of clinical discovery and focused pathophysiology.

In summary, the development and implementation of flow cytometry-based technologies has had major impacts on the diagnosis and classification of disease, monitoring, and prognostication of patients with cancer, as well as patients receiving allogeneic hematopoietic stem cell transplants and solid organ allografts. High-speed sorting of CD34+ cells has provided proof-of-principle data that demonstrate the ability of highly purified hematopoietic stem cells to provide durable and effective hematopoietic reconstitution in patients with malignancies who are undergoing high-dose chemotherapy. The ability of flow cytometry to generate large amounts of multidimensional, high-complexity data that are amenable to high through-put, automated analysis strongly positions this technology as a key platform for use in clinical medicine for decades to come.

1
Van Dilla
M. A.
,
Trujillo
T. T.
,
Mullaney
P. F.
,
Coulter
J. R.
.
1969
.
Cell microfluorometry: a method for rapid fluorescence measurement
.
Science
163
:
1213
1214
.
2
Hulett
H. R.
,
Bonner
W. A.
,
Barrett
J.
,
Herzenberg
L. A.
.
1969
.
Cell sorting: automated separation of mammalian cells as a function of intracellular fluorescence
.
Science
166
:
747
749
.
3
Köhler
G.
,
Milstein
C.
.
1976
.
Derivation of specific antibody-producing tissue culture and tumor lines by cell fusion
.
Eur. J. Immunol.
6
:
511
519
.
4
Herzenberg
L. A.
,
Parks
D.
,
Sahaf
B.
,
Perez
O.
,
Roederer
M.
,
Herzenberg
L. A.
.
2002
.
The history and future of the fluorescence activated cell sorter and flow cytometry: a view from Stanford
.
Clin. Chem.
48
:
1819
1827
.
5
Wood
B. L.
,
Arroz
M.
,
Barnett
D.
,
DiGiuseppe
J.
,
Greig
B.
,
Kussick
S. J.
,
Oldaker
T.
,
Shenkin
M.
,
Stone
E.
,
Wallace
P.
.
2007
.
2006 Bethesda International Consensus recommendations on the immunophenotypic analysis of hematolymphoid neoplasia by flow cytometry: optimal reagents and reporting for the flow cytometric diagnosis of hematopoietic neoplasia
.
Cytometry B Clin. Cytom.
72
(
Suppl. 1
S14
22
.
6
Paiva
B.
,
Vidriales
M. B.
,
Cervero
J.
,
Mateo
G.
,
Perez
J. J.
,
Montalban
M. A.
,
Sureda
A.
,
Montejano
L.
,
Gutierrez
N. C.
,
de Coca
A. G.
, et al
.
2008
.
GEM/PETHEMA Cooperative Study Groups. Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation
.
Blood
112
:
4017
4023
.
7
Swerdlow
S. H.
,
Campo
E.
,
Harris
N. L.
,
Jaffe
E. S.
,
Pileri
S. A.
,
Stein
H.
,
Thiele
J.
,
Vardiman
J.
.
2008
.
WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues
.
World Health Organization Press
,
Geneva
,
Switzerland
.
8
Jaye
D. L.
,
Geigerman
C. M.
,
Herling
M.
,
Eastburn
K.
,
Waller
E. K.
,
Jones
D.
.
2006
.
Expression of the plasmacytoid dendritic cell marker BDCA-2 supports a spectrum of maturation among CD4+CD56+hematodermic neoplasms
.
Mod. Pathol.
19
:
1555
1562
.
9
Kraus
T. S.
,
Sillings
C. N.
,
Saxe
D. F.
,
Li
S. Y.
,
Jaye
D. L.
.
2010
.
The role of CD11c expression in the diagnosis of mantle cell lymphoma
.
Am. J. Clin. Pathol.
134
:
271
277
.
10
Moreton
P.
,
Kennedy
B.
,
Lucas
G.
,
Leach
M.
,
Rassam
S. M.
,
Haynes
A.
,
Tighe
J.
,
Oscier
D.
,
Fegan
C.
,
Rawstron
A.
,
Hillmen
P.
.
2005
.
Eradication of minimal residual disease in B-cell chronic lymphocytic leukemia after alemtuzumab therapy is associated with prolonged survival
.
J. Clin. Oncol.
23
:
2971
2979
.
11
Barnett
D.
,
Walker
B.
,
Landay
A.
,
Denny
T. N.
.
2008
.
CD4 immunophenotyping in HIV infection. Nat. Rev. Microbiol
.
6
(
Suppl. 11
S7
S15
.
12
Oliveira
J. B.
,
Notarangelo
L. D.
,
Fleisher
T. A.
.
2008
.
Applications of flow cytometry for the study of primary immune deficiencies
.
Curr. Opin. Allergy Clin. Immunol.
8
:
499
509
.
13
Waller
E. K.
,
Rosenthal
H.
,
Jones
T. W.
,
Peel
J.
,
Lonial
S.
,
Langston
A.
,
Redei
I.
,
Jurickova
I.
,
Boyer
M. W.
.
2001
.
Larger numbers of CD4(bright) dendritic cells in donor bone marrow are associated with increased relapse after allogeneic bone marrow transplantation
.
Blood
97
:
2948
2956
.
14
Reddy
V.
,
Winer
A. G.
,
Eksioglu
E.
,
Meier-Kriesche
H. U.
,
Schold
J. D.
,
Wingard
J. R.
.
2005
.
Interleukin 12 is associated with reduced relapse without increased incidence of graft-versus-host disease after allogeneic hematopoietic stem cell transplantation
.
Biol. Blood Marrow Transplant.
11
:
1014
1021
.
15
Subramaniyam
V.
,
Waller
E. K.
,
Murrow
J. R.
,
Manatunga
A.
,
Lonial
S.
,
Kasirajan
K.
,
Sutcliffe
D.
,
Harris
W.
,
Taylor
W. R.
,
Alexander
R. W.
,
Quyyumi
A. A.
.
2009
.
Bone marrow mobilization with granulocyte macrophage colony-stimulating factor improves endothelial dysfunction and exercise capacity in patients with peripheral arterial disease
.
Am. Heart J.
158
:
53
60
.
16
Quyyumi
A. A.
,
Waller
E. K.
,
Murrow
J.
,
Esteves
F.
,
Galt
J.
,
Oshinski
J.
,
Lerakis
S.
,
Sher
S.
,
Vaughan
D.
,
Perin
E.
, et al
.
2011
.
CD34(+) cell infusion after ST elevation myocardial infarction is associated with improved perfusion and is dose dependent
.
Am. Heart J.
161
:
98
105
.
17
Civin
C. I.
,
Strauss
L. C.
,
Brovall
C.
,
Fackler
M. J.
,
Schwartz
J. F.
,
Shaper
J. H.
.
1984
.
Antigenic analysis of hematopoiesis. III. A hematopoietic progenitor cell surface antigen defined by a monoclonal antibody raised against KG-1a cells
.
J. Immunol.
133
:
157
165
.
18
Bomberger
C.
,
Singh-Jairam
M.
,
Rodey
G.
,
Guerriero
A.
,
Yeager
A. M.
,
Fleming
W. H.
,
Holland
H. K.
,
Waller
E. K.
.
1998
.
Lymphoid reconstitution after autologous PBSC transplantation with FACS-sorted CD34+ hematopoietic progenitors
.
Blood
91
:
2588
2600
.
19
Tricot
G.
,
Gazitt
Y.
,
Leemhuis
T.
,
Jagannath
S.
,
Desikan
K. R.
,
Siegel
D.
,
Fassas
A.
,
Tindle
S.
,
Nelson
J.
,
Juttner
C.
, et al
.
1998
.
Collection, tumor contamination, and engraftment kinetics of highly purified hematopoietic progenitor cells to support high dose therapy in multiple myeloma
.
Blood
91
:
4489
4495
.
20
Müller
A. M.
,
Kohrt
H. E.
,
Cha
S.
,
Laport
G.
,
Klein
J.
,
Guardino
A. E.
,
Johnston
L. J.
,
Stockerl-Goldstein
K. E.
,
Hanania
E.
,
Juttner
C.
, et al
.
2012
.
Long-term outcome of patients with metastatic breast cancer treated with high-dose chemotherapy and transplantation of purified autologous hematopoietic stem cells
.
Biol. Blood Marrow Transplant.
18
:
125
133
.
21
Michallet
M.
,
Philip
T.
,
Philip
I.
,
Godinot
H.
,
Sebban
C.
,
Salles
G.
,
Thiebaut
A.
,
Biron
P.
,
Lopez
F.
,
Mazars
P.
, et al
.
2000
.
Transplantation with selected autologous peripheral blood CD34+Thy1+ hematopoietic stem cells (HSCs) in multiple myeloma: impact of HSC dose on engraftment, safety, and immune reconstitution
.
Exp. Hematol.
28
:
858
870
.
22
Vose
J. M.
,
Bierman
P. J.
,
Lynch
J. C.
,
Atkinson
K.
,
Juttner
C.
,
Hanania
C. E.
,
Bociek
G.
,
Armitage
J. O.
.
2001
.
Transplantation of highly purified CD34+Thy-1+ hematopoietic stem cells in patients with recurrent indolent non-Hodgkin's lymphoma
.
Biol. Blood Marrow Transplant.
7
:
680
687
.
23
Roncador
G.
,
Brown
P. J.
,
Maestre
L.
,
Hue
S.
,
Martinez-Torrecuadrada
J. L.
,
Ling
K. L.
,
Pratap
S.
,
Toms
C.
,
Fox
B. C.
,
Cerundolo
V.
, et al
.
2005
.
Analysis of FOXP3 protein expression in human CD4+CD25+ regulatory T cells at the single-cell level
.
Eur. J. Immunol.
35
:
1681
1691
.
24
Garovoy
M. R.
,
Rheinschmidt
M. A.
,
Bigos
M.
,
Perkins
H.
,
Colombe
B.
,
Feduska
N.
,
Salvatierra
O.
.
1983
.
Flow cytometry analysis: A high technology crossmatch technique facilitating transplantation
.
Transplant. Proc.
15
:
1939
1941
.
25
Bray
R. A.
,
Tarsitani
C.
,
Gebel
H. M.
,
Lee
J. H.
.
2011
.
Clinical cytometry and progress in HLA antibody detection
.
Methods Cell Biol.
103
:
285
310
.
26
Lindemann
M.
,
Nyadu
B.
,
Heinemann
F. M.
,
Kribben
A.
,
Paul
A.
,
Horn
P. A.
,
Witzke
O.
.
2010
.
High negative predicative value of an amplified flow cytometry crossmatch in living donor kidney transplantation
.
Hum. Immunol.
71
:
771
776
.
27
Spellman
S.
,
Bray
R.
,
Rosen-Bronsen
S.
,
Haagenson
M.
,
Klein
J.
,
Flesh
S.
,
Vierra-Green
C.
,
Anasetti
C.
.
2010
.
The detection of donor-directed HLA-specific alloantibodies in recipients of unrelated hematopoietic cell transplantation is predictive of graft failure
.
Blood
115
:
2704
2708
.
28
Ciurea
S. O.
,
deLima
M.
,
Cano
P.
,
Korbling
M.
,
Giralt
S.
,
Shpall
E. J.
,
Wang
X.
,
Thall
P. F.
,
Champlin
R. E.
,
Fernandez-Vina
M.
.
2009
.
High risk of graft failure in patients with anti-HLA antibodies undergoing haploidentical stem-cell transplantation
.
Transplantation
88
:
1019
1024
.
29
Taylor
J. D.
,
Briley
D.
,
Nguyen
Q.
,
Long
K.
,
Iannone
M. A.
,
Li
M. S.
,
Ye
F.
,
Afshari
A.
,
Lai
E.
,
Wagner
M.
, et al
.
2001
.
Flow cytometric platform for high-throughput single nucleotide polymorphism analysis
.
Biotechniques
30
:
661
666, 668–669
.
30
Couzi
L.
,
Araujo
C.
,
Guidicelli
G.
,
Bachelet
T.
,
Moreau
K.
,
Morel
D.
,
Robert
G.
,
Wallerand
H.
,
Moreau
J. F.
,
Taupin
J. L.
,
Merville
P.
.
2011
.
Interpretation of positive flow cytometric crossmatch in the era of the single-antigen bead assay
.
Transplantation
91
:
527
535
.
31
Cecka
J. M.
,
Kucheryavaya
A. Y.
,
Reinsmoen
N. L.
,
Leffell
M. S.
.
2011
.
Calculated PRA: initial results show benefits for sensitized patients and a reduction in positive crossmatches
.
Am. J. Transplant.
11
:
719
724
.
32
Cesbron-Gautier
A.
,
Simon
P.
,
Achard
L.
,
Cury
S.
,
Follea
G.
,
Bignon
J. D.
.
2004
.
Luminex technology for HLA typing by PCR-SSO and identification of HLA antibody specificities
.
Ann. Biol. Clin. (Paris)
62
:
93
98
.

The authors have no financial conflicts of interest.